RHYTHM PHARMACEUTICALS, INC.

This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities

Litigation Reform Act of 1995. All statements contained in this Current Report that do not relate to matters of historical

fact should be considered forward-looking statements, including without limitation statements regarding the Company’s

anticipated financial performance for any period of time, including preliminary unaudited revenues, for the fourth quarter

and full year ending December 31, 2025; the potential, safety, efficacy, and regulatory and clinical progress, potential

regulatory submissions, approvals and timing thereof of setmelanotide and other product candidates, including

bivamelagon (LB54640) and RM-718; the announcement of data from our clinical trials, including our global Phase 3 trial

evaluating setmelanotide in patients with acquired hypothalamic obesity; the ongoing enrollment of patients in our clinical

trials; our participation in upcoming events and presentations; and the timing of any of the foregoing. Statements using

words such as “expect”, “anticipate”, “believe”, “may”, “will”, “aim” and similar terms are also forward-looking

statements. Such statements are subject to numerous risks and uncertainties, including, but not limited to, our actual

financial results for the fourth quarter and full year 2025 may differ from our preliminary estimates; our ability to enroll

patients in clinical trials, the design and outcome of clinical trials, the ability to achieve necessary regulatory approvals,

risks associated with data analysis and reporting, failure to identify and develop additional product candidates, unfavorable

pricing regulations, third-party reimbursement practices or healthcare reform initiatives, risks associated with the laws and

regulations governing our international operations and the costs of any related compliance programs, the impact of

competition, risks relating to product liability lawsuits, inability to maintain collaborations, or the failure of these

collaborations, our reliance on third parties, risks relating to intellectual property, our ability to hire and retain necessary

personnel, general economic conditions, risks related to internal control over financial reporting, and the other important

factors discussed under the caption “Risk Factors” in our Quarterly Report on Form 10-Q for the quarter ended September

30, 2025 and our other filings with the Securities and Exchange Commission. Except as required by law, we undertake no

obligations to make any revisions to the forward-looking statements contained in this Current Report release or to update

them to reflect events or circumstances occurring after the date of this Current Report, whether as a result of new

information, future developments or otherwise.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

The following Exhibits 99.1 and 99.2 relate to Items 2.02 and 7.01, respectively and shall be deemed to be furnished, and

not filed: